公开(公告)号：US08323644B2

公开(公告)日：2012-12-04

申请号：US12161285

申请日：2007-01-17

申请人： Nai-Kong V. Cheung ,  Rolf Einar Engstad

发明人： Nai-Kong V. Cheung ,  Rolf Einar Engstad

IPC分类号： A61K39/395 ,  A61K31/716 ,  C07K16/28 ,  C07K16/30

CPC分类号： A61K39/39 ,  A61K31/716 ,  A61K39/0011 ,  A61K39/39558 ,  A61K2039/542 ,  A61K2039/55511 ,  C07K16/3084 ,  C08L5/00 ,  A61K2300/00

摘要： A therapeutic composition for treatment of cancer in a mammal is disclosed. The composition comprises an effective amount of a yeast beta-glucan composition which is suitable for oral administration and for absorption through the gastrointestinal tract of the mammal. The above therapeutic composition may further comprise antitumor antibodies or cancer vaccine composition, wherein the antitumor activities of the antitumor antibodies or the cancer vaccine composition are enhanced by the yeast glucan.

摘要翻译： 公开了一种用于治疗哺乳动物癌症的治疗组合物。 组合物包含有效量的酵母β-葡聚糖组合物，其适于口服给药并通过哺乳动物的胃肠道吸收。 上述治疗组合物还可以包含抗肿瘤抗体或癌症疫苗组合物，其中抗肿瘤抗体或癌症疫苗组合物的抗肿瘤活性被酵母葡聚糖增强。

公开(公告)号：US08501471B2

公开(公告)日：2013-08-06

申请号：US12797081

申请日：2010-06-09

申请人： Nai-Kong V. Cheung

发明人： Nai-Kong V. Cheung

IPC分类号： C12N5/07

CPC分类号： C07K16/30 ,  A01K2217/05 ,  A61K51/1066 ,  A61K51/1078 ,  A61K2039/505 ,  C07K16/3053 ,  C07K16/3084 ,  C07K16/4266 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2319/00

摘要： This invention provides a composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a suitable carrier. This invention provides a pharmaceutical composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a pharmaceutically acceptable carrier. This invention also provides an antibody other than the monoclonal antibody 8H9 comprising the complementary determining regions of monoclonal antibody 8H9 or a derivative thereof, capable of binding to the same antigen as the monoclonal antibody 8H9. This invention provides a substance capable of competitively inhibiting the binding of monoclonal antibody 8H9. This invention also provides an isolated scFv of monoclonal antibody 8H9 or a derivative thereof. This invention also provides the 8H9 antigen. This invention also provides a method of inhibiting the growth of tumor cells comprising contacting said tumor cells with an appropriate amount of monoclonal antibody 8H9 or a derivative thereof.

公开(公告)号：US08148154B2

公开(公告)日：2012-04-03

申请号：US12709848

申请日：2010-02-22

申请人： Nai-Kong V. Cheung ,  Hong-fen Guo

发明人： Nai-Kong V. Cheung ,  Hong-fen Guo

IPC分类号： G01N33/53 ,  C12N15/12

CPC分类号： C07K16/4266 ,  A01K2217/05 ,  A61K47/6865 ,  A61K47/6873 ,  A61K49/0004 ,  A61K49/0006 ,  A61K51/1045 ,  A61K2039/505 ,  C07K16/00 ,  C07K16/18 ,  C07K16/30 ,  C07K16/3053 ,  C07K16/3084 ,  C07K16/4208 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/732 ,  C07K2317/77 ,  C07K2319/00

摘要： This invention provides a method for identifying cells expressing a target single chain antibody (scFv) directed against a target antigen from a collection of cells that includes cells that do not express the target scFv, comprising the step of combining the collection of cells with an anti-idiotype directed to an antibody specific for the target antigen and detecting interaction, if any, of the anti-idiotype with the cells, wherein the occurrence of an interaction identifies the cell as one which expresses the target scFv. This invention also provides a method for making a single chain antibody (scFv) directed against an antigen, wherein the selection of clones is made based upon interaction of those clones with an appropriate anti-idiotype, and heretofore inaccessible scFv so made. This invention provides the above methods or any combination thereof. Finally, this invention provides various uses of these methods.

摘要翻译： 本发明提供了从包含不表达靶标scFv的细胞的细胞集合中鉴定表达靶抗原的目标单链抗体（scFv）的细胞的方法，包括将细胞收集与抗 - 针对针对靶抗原特异性的抗体，并检测与细胞的抗独特型相互作用（如果有的话），其中相互作用的发生将细胞识别为表达靶scFv的细胞。 本发明还提供了制备针对抗原的单链抗体（scFv）的方法，其中克隆的选择基于那些克隆与适当的抗独特型的相互作用，以及如此制备的迄今为止不可接近的scFv。 本发明提供了上述方法或其任何组合。 最后，本发明提供了这些方法的各种用途。

公开(公告)号：US08633170B2

公开(公告)日：2014-01-21

申请号：US12854603

申请日：2010-08-11

申请人： Nai-Kong V. Cheung

发明人： Nai-Kong V. Cheung

IPC分类号： C08B37/00 ,  A61K31/716

CPC分类号： A61K39/39 ,  A61K31/715 ,  A61K31/716 ,  A61K31/739 ,  A61K39/39541 ,  A61K39/39558 ,  A61K39/44 ,  A61K47/36 ,  A61K2039/55583 ,  C08B37/0024 ,  A61K2300/00

摘要： This invention provides a composition comprising an effective amount of glucan capable of enhancing efficacy of antibodies. This invention further provides the above compositions and a pharmaceutically acceptable carrier. This invention also provides a method for treating a subject with cancer comprising administrating the above-described composition to the subject. This invention provides a composition comprising effective amount of glucan capable of enhancing efficacy of vaccines. This invention also provides a method of treating a subject comprising administrating the above pharmaceutical composition to the subject. This invention provides a composition comprising effective amount of glucan capable of enhancing efficacy of natural antibodies. This invention provides a composition comprising effective amount of glucan capable of enhancing host immunity. This invention also provides a composition comprising effective amount of glucan capable of enhancing the action of an agent in preventing tissue rejection.

公开(公告)号：US07906492B2

公开(公告)日：2011-03-15

申请号：US11334763

申请日：2006-01-17

申请人： Nai-Kong V. Cheung

发明人： Nai-Kong V. Cheung

IPC分类号： A61K31/7105 ,  A61K31/711 ,  A61K31/716 ,  C08L5/00 ,  C08B37/00

CPC分类号： A61K47/26 ,  A61K31/00 ,  A61K31/715 ,  A61K31/739 ,  A61K39/39 ,  A61K39/39558 ,  A61K39/44 ,  A61K47/36 ,  A61K48/00 ,  C08L5/00 ,  A61K2300/00

摘要： A therapeutic composition for treatment of cancer in a mammal is disclosed. The composition comprises an effective amount of a glucan composition which is suitable for oral administration and for absorption through the gastrointestinal tract of the mammal, and at least one antibody for the cancer. A method of treating cancer in a mammal is also disclosed. The method comprises administering a suitable orally administered glucan and at least one antibody for the treatment of cancer to the mammal. In addition a composition for delivery of peptide, protein, RNA, DNA or plasmid comprising effective amount of a beta-glucan is disclosed.

摘要翻译： 公开了一种用于治疗哺乳动物癌症的治疗组合物。 该组合物包含有效量的适于口服给药和通过哺乳动物胃肠道吸收的葡聚糖组合物和至少一种癌症抗体。 还公开了一种治疗哺乳动物癌症的方法。 该方法包括向哺乳动物施用合适的口服葡聚糖和至少一种用于治疗癌症的抗体。 此外，公开了用于递送肽，蛋白质，RNA，DNA或包含有效量的β-葡聚糖的质粒的组合物。

公开(公告)号：US07704973B2

公开(公告)日：2010-04-27

申请号：US10565484

申请日：2004-07-16

申请人： Nai-Kong V. Cheung

发明人： Nai-Kong V. Cheung

IPC分类号： A61K31/716 ,  C07H3/00 ,  C07H3/06

CPC分类号： A61K39/39 ,  A61K31/715 ,  A61K31/716 ,  A61K31/739 ,  A61K39/39541 ,  A61K39/39558 ,  A61K39/44 ,  A61K47/36 ,  A61K2039/55583 ,  C08B37/0024 ,  A61K2300/00

摘要： This invention provides a method for introducing substances into cells comprising contacting a composition comprising orally administered beta-glucan with said cells. This invention also provides a method for introducing substances into a subject comprising administering to the subject an effective amount of the above compositions. The substance, which could be delivered orally includes but is not limited to peptides, proteins, RNAs, DNAs, chemotherapeutic agents, biologically active agents, plasmids, and other small molecules and compounds. Finally, this invention provides a composition comprising orally administered beta-glucan capable of enhancing efficacy of IgM and different uses of the said composition.

摘要翻译： 本发明提供了将物质引入细胞的方法，包括使包含口服β-葡聚糖的组合物与所述细胞接触。 本发明还提供了将物质引入受试者的方法，包括向受试者施用有效量的上述组合物。 可以口服递送的物质包括但不限于肽，蛋白质，RNA，DNA，化学治疗剂，生物活性剂，质粒和其他小分子和化合物。 最后，本发明提供一种组合物，其包含能够增强IgM的功效和所述组合物的不同用途的口服β-葡聚糖。

公开(公告)号：US06939948B1

公开(公告)日：2005-09-06

申请号：US10395434

申请日：2003-03-24

申请人： Soldano Ferrone ,  Chun-Yen Tsao ,  Xinhui Wang ,  Wei Luo ,  Nai-Kong V. Cheung

发明人： Soldano Ferrone ,  Chun-Yen Tsao ,  Xinhui Wang ,  Wei Luo ,  Nai-Kong V. Cheung

IPC分类号： A61K38/00 ,  C07K5/00 ,  C07K14/47 ,  C07K14/78

CPC分类号： C07K14/78 ,  A61K38/00 ,  C07K14/4748

摘要： The present invention provides peptide mimics for GD2 ganglioside. The peptide mimics were identified by panning phage display peptide libraries with an anti-GD2 monoclonal antibody. The identified peptide mimics can be used as immunogens for cancer therapy such as for melanoma and neuroblastoma.

摘要翻译： 本发明提供GD2神经节苷脂的肽模拟物。 通过用抗GD2单克隆抗体淘选噬菌体展示肽文库来鉴定肽模拟物。 鉴定的肽模拟物可用作癌症治疗的免疫原，例如用于黑素瘤和神经母细胞瘤。

公开(公告)号：US06451995B1

公开(公告)日：2002-09-17

申请号：US09142974

申请日：1998-09-18

申请人： Nai-Kong V. Cheung ,  Steven M. Larson ,  Hong-Fen Guo ,  Ken Rivlin ,  Michel Sadelain

发明人： Nai-Kong V. Cheung ,  Steven M. Larson ,  Hong-Fen Guo ,  Ken Rivlin ,  Michel Sadelain

IPC分类号： C12N1513

CPC分类号： C07K16/3084 ,  A61K47/6898 ,  A61K47/6899 ,  B82Y5/00 ,  C07K14/36 ,  C07K14/70517 ,  C07K16/30

摘要： Recombinant antibody constructs comprise the variable regions of the heavy and light chains of anti-GD2 antibodies. These antibody constructs may be coupled to a label such as a radiolabel or to a protein such as streptavidin or pro-drug converting enzymes for use in imaging or therapeutic applications. The antibody constructs may also be transduced into T cells to produce populations of T cells which target GD2-producing tumor cells.

摘要翻译： 重组抗体构建体包含抗GD2抗体的重链和轻链的可变区。 这些抗体构建体可以偶联到诸如放射性标记的标记物或蛋白质例如链霉亲和素或前药转化酶，用于成像或治疗应用。 抗体构建体也可以被转导入T细胞以产生靶向产生GD2的肿瘤细胞的T细胞群体。

公开(公告)号：US4539292A

公开(公告)日：1985-09-03

申请号：US454219

申请日：1982-12-29

申请人： Michael J. Reid ,  J. Michael Kwasnicki ,  Nai-Kong V. Cheung

发明人： Michael J. Reid ,  J. Michael Kwasnicki ,  Nai-Kong V. Cheung

IPC分类号： G01N33/68 ,  G01N33/54

CPC分类号： G01N33/6854 ,  Y10S435/962 ,  Y10S436/825

摘要： Using monoclonal mouse anti-human IgE antibodies, the microtiter solid phase radioimmunoassay (MSPRIA) and the enzyme-linked immunoabsorbent assay (EILSA) were modified to quantitatively measure honeybee venom (HBV) and perennial rye grass (PRG) specific immunoglobulin E (sIgE). By using a novel dilution, serial transfer and cummulative counting technique, the inhibiting and interfering effects of specific immunoglobulin G (sIgG) in the assay of (sIgE) can be reduced and the quantitative determination of (sIgE) accomplished with precision and reliability.

摘要翻译： 使用单克隆小鼠抗人IgE抗体，修饰微量滴定固相放射免疫测定（MSPRIA）和酶联免疫吸附测定（EILSA），定量测定蜜蜂毒液（HBV）和多年生黑麦草（PRG）特异性免疫球蛋白E（sIgE） 。 通过使用新型稀释，连续转移和累积计数技术，可以减少特异性免疫球蛋白G（sIgG）在（sIgE）测定中的抑制和干扰作用，并以精确和可靠的方式实现（sIgE）的定量测​​定。

公开(公告)号：US07737258B2

公开(公告)日：2010-06-15

申请号：US10097558

申请日：2002-03-08

申请人： Nai-Kong V. Cheung

发明人： Nai-Kong V. Cheung

IPC分类号： C07K16/46

CPC分类号： C07K16/3053 ,  A01K2217/05 ,  A61K47/6865 ,  A61K47/6873 ,  A61K49/0004 ,  A61K49/0006 ,  A61K51/1045 ,  A61K2039/505 ,  C07K16/00 ,  C07K16/18 ,  C07K16/30 ,  C07K16/3084 ,  C07K16/4208 ,  C07K16/4266 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/732 ,  C07K2317/77 ,  C07K2319/00

摘要： This invention provides a composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a suitable carrier. This invention provides a pharmaceutical composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a pharmaceutically acceptable carrier. This invention also provides an antibody other than the monoclonal antibody 8H9 comprising the complementary determining regions of monoclonal antibody 8H9 or a derivative thereof, capable of binding to the same antigen as the monoclonal antibody 8H9. This invention provides a substance capable of competitively inhibiting the binding of monoclonal antibody 8H9. This invention also provides an isolated scFv of monoclonal antibody 8H9 or a derivative thereof. This invention also provides the 8H9 antigen. This invention also provides a method of inhibiting the growth of tumor cells comprising contacting said tumor cells with an appropriate amount of monoclonal antibody 8H9 or a derivative thereof.

摘要翻译： 本发明提供了包含有效量的单克隆抗体8H9或其衍生物和合适的载体的组合物。 本发明提供了包含有效量的单克隆抗体8H9或其衍生物和药学上可接受的载体的药物组合物。 本发明还提供除单克隆抗体8H9之外的抗体，其包含能够与单克隆抗体8H9结合相同抗原的单克隆抗体8H9或其衍生物的互补决定区。 本发明提供能够竞争性抑制单克隆抗体8H9结合的物质。 本发明还提供单克隆抗体8H9或其衍生物的分离的scFv。 本发明还提供了8H9抗原。 本发明还提供抑制肿瘤细胞生长的方法，包括使所述肿瘤细胞与适量的单克隆抗体8H9或其衍生物接触。